ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

erfonrilimab

Also written as “KN046”, “GT90001+KN046” and “KN046 (PD-L1/CTLA4 BsAb)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Thymoma · Lymphoma · Triple Negative Breast Neoplasms, led by 4 companies.

Drug pageErfonrilimab: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 13, 202014 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncologyits history only111 open or runningphase 3since Jul 13, 2020May 8, 2018none ahead
Suzhou Kintor Pharmaceutical11 open or runningphase 2since Jul 5, 2021Jul 5, 2021none ahead
Suzhou Zelgen Biopharmaceuticalsits history only10 open or runningphase 2since Oct 29, 2020Oct 29, 2020none ahead
Zhejiang Raygene Pharmaceuticalsits history only10 open or runningphase 2since Feb 13, 2025Feb 13, 2025none ahead

Also a collaborator on its studies: Sunshine Lake Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Suzhou Kintor Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named erfonrilimabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, KN046
  2. Jul 5, 2021First study: phase 2 study in Solid TumorFirst studyNCT04984668 · 216 planned · Taiwan

TargetBeta

CD274 →CTLA4 →read by rule
“A bispecific monoclonal antibody directed against both the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Studies

The one study Suzhou Kintor Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04984668Solid Tumor · Taiwan2RecruitingApr 2025216

How it is read

Names in the registry

  • “KN046”, 11 entries
  • “GT90001+KN046”, 4 entries
  • “KN046 (PD-L1/CTLA4 BsAb)”, 2 entries
  • “KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)”, 1 entry
  • “KN046 Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.